Milestone Pharmaceuticals Faces Increased Risk Amid Mixed Technical and Valuation Signals

Milestone Pharmaceuticals, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation that reflects notable shifts in its financial metrics and market position. The stock's score has transitioned from 'Not Rated' to 'Sell' as of March 20, 2026, primarily due to changes in both technical and valuation grades. The technical indicators present a mixed picture, with the MACD signaling bearish trends on a weekly basis, while the monthly outlook shows a mildly bullish stance. However, other metrics such as Bollinger Bands and moving averages indicate bearish conditions. This divergence suggests a complex technical landscape for the stock. On the valuation front, Milestone Pharmaceuticals is now classified as risky, with a P/E ratio that remains unreported due to losses. The price-to-book value stands at 7.02, while the EV to EBITDA and EV to EBIT ratios are negative, indicating challenges in profitability. The company has also reported a negative return on equity of -282.97%, further emphasizing its current financial difficulties. Overall, the recent evaluation adjustment highlights the underlying trends and events impacting Milestone Pharmaceuticals, reflecting a cautious outlook based on its financial metrics and market performance. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.